TL;DR
- Progesterone is not routinely recommended in standard feminising HRT guidelines — this reflects insufficient evidence, not evidence of ineffectiveness
- The clinical trial evidence specifically in trans women is very limited; most data comes from small studies and extrapolation from cisgender women
- Micronised progesterone (chemically identical to endogenous human progesterone) is not equivalent to synthetic progestins — the distinction matters clinically
- Available evidence suggests micronised progesterone may be associated with a more favourable breast cancer risk profile than some synthetic progestins, although uncertainty remains
- Neither strong benefit nor strong harm has been demonstrated — that is probably the most defensible summary of the current evidence
Progesterone is not part of standard feminising HRT protocols for trans women. Most mainstream guidelines do not recommend its routine use. Most prescribers don’t offer it. But the conversation around it is growing, and it deserves an honest assessment of what the evidence actually shows — and what it does not.
What progesterone is — and what it isn’t
Progesterone is a steroid hormone produced primarily by the corpus luteum after ovulation in cisgender women, with levels rising substantially during the luteal phase and throughout pregnancy. It acts on progesterone receptors throughout the body, including in breast tissue, the brain, bone, and the cardiovascular system.
The primary form used in trans women is micronised progesterone — a compound chemically identical to endogenous human progesterone. This is distinct from synthetic progestins such as medroxyprogesterone acetate (MPA) or the progestogenic activity of cyproterone acetate. Synthetic progestins have different pharmacological profiles and are not equivalent to progesterone — in either their benefits or their risks. This distinction is clinically important and frequently overlooked.
What the evidence supports
The honest answer is: not much, specifically in trans women. Clinical trial evidence in this population is very limited. Most data comes from anecdotal reports, small observational studies, and extrapolation from cisgender women’s data.
A 2024 narrative review (Szymczyk et al., Journal of Clinical Medicine) identified potential areas of benefit, including breast development and sleep quality, while acknowledging that the evidence base is weak and robust randomised controlled trial data are lacking.
A 2024 retrospective cohort study (Bahr et al., Journal of the American Pharmacists Association) compared 88 trans women using feminising HRT with and without progesterone. The progesterone group reported significantly higher satisfaction with breast development at both 6 months (53.8% vs. 19.6%) and 9 months (71.4% vs. 20.8%), and showed significantly better provider-documented mental health at 6 months, though that difference was not sustained at 9 months. There was no significant difference between groups in testosterone suppression, weight change, or libido satisfaction. This was a small, retrospective study rather than a randomised trial, and breast development was assessed by patient satisfaction rather than objective measurement — but it represents an encouraging signal warranting further investigation, not an absence of difference.
Why it’s absent from guidelines
Progesterone is absent from current mainstream guidelines because the evidence for benefit is not yet sufficient to drive a formal recommendation. Importantly, guideline omission reflects insufficient evidence rather than evidence of ineffectiveness. Current recommendations are based on uncertainty, not on proof that progesterone provides no benefit. This is not the same as evidence of harm — a distinction that is frequently misunderstood.
Breast cancer risk
Synthetic progestins — particularly medroxyprogesterone acetate used in older combined HRT formulations — have been associated with increased breast cancer risk in postmenopausal cisgender women, most notably in the Women’s Health Initiative (Rossouw et al., JAMA 2002). This finding is specific to certain synthetic progestins and cannot be directly extrapolated to micronised progesterone or to trans women.
Available evidence from postmenopausal cisgender women suggests micronised progesterone may be associated with a more favourable breast cancer risk profile than some synthetic progestins, although uncertainty remains. Long-term data specifically in trans women are very limited, and no firm conclusions can be drawn.
Cyproterone acetate is not progesterone
Cyproterone acetate, commonly used as an antiandrogen in trans women in many countries, is a potent synthetic progestogen. Its well-documented associations — including hyperprolactinaemia and rare meningioma risk with long-term use — are relevant to its specific pharmacological profile. These risks should not be attributed to progesterone as a class, nor should CPA’s antiandrogen efficacy be taken as evidence for or against micronised progesterone.
Route of administration matters
If progesterone is used, route of administration has meaningful pharmacological consequences. Oral micronised progesterone undergoes significant first-pass hepatic metabolism, with substantial conversion to neuroactive metabolites including allopregnanolone — a GABA-A receptor modulator that may partly explain reported effects on mood and sleep. Vaginal administration results in less first-pass metabolism and lower production of these neuroactive metabolites, with a different systemic metabolite profile. Neither route is universally superior; the choice depends on clinical context and patient goals.
The clinical picture
Progesterone is used by a substantial number of trans women, particularly in informed consent settings, and many report tolerating it well. Neither strong benefit nor strong harm has been demonstrated — that is probably the most scientifically defensible summary of the current evidence. Expectations should be calibrated accordingly, and decisions made in the context of an informed conversation with a prescriber who understands the distinction between micronised progesterone and synthetic progestins.
⚠️ Clinical note: The above reflects the current state of evidence and uncertainty. The breast cancer risk data from the WHI applies to specific synthetic progestins, not to micronised progesterone — this distinction is clinically important. Trans women considering progesterone should ensure their prescriber is aware of which form is being discussed.
Sources
- Szymczyk S, Mączka K, Mądrzak L, Grymowicz M, Smolarczyk R. The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population—A Narrative Review. J Clin Med. 2024;13(22):6795.
- Bahr C, Ewald J, Dragovich R, Gothard MD. Effects of Progesterone on Gender Affirmation Outcomes as Part of Feminizing Hormone Therapy. J Am Pharm Assoc. 2024;64(1):268–272.
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321–333.
- Millward CP, Keshwara SM, Islim AI, Jenkinson MD, Alalade AF, Gilkes CE. Development and Growth of Intracranial Meningiomas in Transgender Women Taking Cyproterone Acetate as Gender-Affirming Progestogen Therapy: A Systematic Review. Transgend Health. 2022;7(6):473–483.
